Acrivon Therapeutics (ACRV) Institutional Ownership $1.26 -0.02 (-1.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)19TotalInstitutional Inflows(last 12 months)$23.16MNumber ofInstitutional Sellers(last 12 months)13TotalInstitutional Outflows(last 12 months)$3.11M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails6/27/2025Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183% 5/16/2025Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183% 5/15/2025Baker BROS. Advisors LP22,809$46K0.0%-56.9%0.073% 5/13/2025Wealthedge Investment Advisors LLC56,467$115K0.1%+420.1%0.180% 5/12/2025Nuveen LLC13,402$27K0.0%N/A0.043% 5/12/2025Invesco Ltd.35,315$72K0.0%N/A0.113% 3/12/2025Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035% 2/17/2025Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043% 2/17/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC102,784$619K0.0%+29.7%0.330% 2/17/2025Corton Capital Inc.12,159$73K0.0%N/A0.039% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240% 2/17/2025Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807% 2/17/2025Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301% 2/14/2025Northern Trust Corp117,323$706K0.0%+11.3%0.377% 2/14/2025Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119% 2/13/2025Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920% 2/13/2025Barclays PLC38,091$228K0.0%+14.4%0.122% 2/13/2025Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159% 2/12/2025Trexquant Investment LP16,871$102K0.0%-44.5%0.054% 2/12/2025JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083% 2/11/2025American Century Companies Inc.17,588$106K0.0%+14.2%0.056% 2/6/2025Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366% 2/4/2025Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089% 1/24/2025China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109% 12/13/2024Exome Asset Management LLC116,757$817K0.5%N/A0.375% 11/19/2024Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% 8/16/2024Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone.5/15/2024Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% 5/14/2024American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023Barclays PLC14,263$184K0.0%-16.0%0.065% 8/10/2023AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward) ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 34 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Marshall Wace LLP ($3.60M), Acorn Capital Advisors LLC ($2.44M), and Federated Hermes Inc. ($2.16M).Learn more on Acrivon Therapeutics' institutional investors. What percentage of Acrivon Therapeutics' stock is owned by institutional investors? 71.62% of Acrivon Therapeutics' stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics' stock? Of the 26 institutional investors that purchased Acrivon Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Exome Asset Management LLC ($116.76K), Wealthedge Investment Advisors LLC ($56.47K), and Baker BROS. Advisors LP ($52.89K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 3,991,592 shares in the last 24 months. This purchase volume represents approximately $23.16M in transactions. Which of Acrivon Therapeutics' major shareholders have been selling company stock? Of the 13 institutional investors that sold Acrivon Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Goldman Sachs Group Inc. ($360.07K), Marshall Wace LLP ($212.07K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($30.12K), Baker BROS. Advisors LP ($30.08K), Exchange Traded Concepts LLC ($22.52K), and Citadel Advisors LLC ($20.98K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 768,539 shares in the last 24 months. This volume of shares sold represents approximately $3.11M in transactions. Related Companies Voyager Therapeutics Institutional Ownership Journey Medical Institutional Ownership Alector Institutional Ownership Lifevantage Institutional Ownership I-Mab Institutional Ownership Black Diamond Therapeutics Institutional Ownership BioAge Labs Institutional Ownership Puma Biotechnology Institutional Ownership Nuvectis Pharma Institutional Ownership C4 Therapeutics Institutional Ownership This page (NASDAQ:ACRV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
